Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus 10-day decitabine versus 10-day decitabine in unfit older patients with AML or high-risk MDS
NL-OMON19923Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) comparing Decitabine with Ibrutinib + decitabine (2 arms). Primary endpoint: Cumulative CR/CRi rate after 3 cycles. Started Sep 2016; status: recruiting.
02
Drugs
ibrutinibdecitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON19923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON19923.